progynova ts 100micrograms/24hours transdermal patches
bayer plc - estradiol - transdermal patch - 100microgram/24hour
progynova ts 50micrograms/24hours transdermal patches
bayer plc - estradiol - transdermal patch - 50microgram/24hour
b-patch buprenorphine 15 microgram/hour transdermal drug delivery system sachet
au pharma pty ltd - buprenorphine, quantity: 15 mg - drug delivery system, transdermal - excipient ingredients: povidone; levulinic acid; oleyl oleate; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; glycidyl methacrylate; 2-hydroxyethyl acrylate - b-patch patches are indicated for the management of severe pain where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - requires daily, continuous, long-term treatment,b-patch patches are not indicated for use in chronic non-cancer pain other than in exception circumstances. b-patch patches are not indicated as an as-needed (prn) analgesia.
b-patch buprenorphine 5 microgram/hour transdermal drug delivery system pouches
au pharma pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: povidone; oleyl oleate; polyethylene terephthalate; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; glycidyl methacrylate; 2-hydroxyethyl acrylate - b-patch patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,b-patch patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. b-patch patches are not indicated as an as-needed (prn) analgesia.
b-patch buprenorphine 10 microgram/hour transdermal drug delivery system pouches
au pharma pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; levulinic acid; oleyl oleate; povidone; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; glycidyl methacrylate; 2-hydroxyethyl acrylate - b-patch patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,b-patch patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. b-patch patches are not indicated as an as-needed (prn) analgesia.
b-patch buprenorphine 20 microgram/hour transdermal drug delivery system pouches
au pharma pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; povidone; polyethylene terephthalate; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; glycidyl methacrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate; butyl acrylate; acrylic acid; aluminium acetylacetonate; heptane - b-patch patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,b-patch patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. b-patch patches are not indicated as an as-needed (prn) analgesia.
exelon 4.6mg24hours transdermal patches
novartis pharmaceuticals uk ltd - rivastigmine - transdermal patch - 4.6mg/24hour
exelon 9.5mg24hours transdermal patches
novartis pharmaceuticals uk ltd - rivastigmine - transdermal patch - 9.5mg/24hour
fencino 12micrograms/hour transdermal patches
luye pharma ltd - fentanyl - transdermal patch - 12microgram/1hour
fencino 25micrograms/hour transdermal patches
luye pharma ltd - fentanyl - transdermal patch - 25microgram/1hour